Free Trial
→ Do NOT Buy SpaceX – Do This Instead (From Stansberry Research) (Ad)tc pixel Free EVLO Stock Alerts

Evelo Biosciences (EVLO) Competitors

Evelo Biosciences logo
$0.0002 0.00 (0.00%)
As of 10/13/2026
Compare

EVLO vs. TRVN, BPTH, NAVB, PXMD, and SCPS

Should you buy Evelo Biosciences stock or one of its competitors? Evelo Biosciences's main competitors and comparable companies include Trevena (TRVN), Bio-Path (BPTH), Navidea Biopharmaceuticals (NAVB), PaxMedica (PXMD), and Scopus BioPharma (SCPS). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Evelo Biosciences compare to Trevena?

Trevena (NASDAQ:TRVN) and Evelo Biosciences (NASDAQ:EVLO) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, media sentiment, profitability, analyst recommendations, valuation, risk, dividends and institutional ownership.

In the previous week, Trevena's average media sentiment score of 0.00 equaled Evelo Biosciences'average media sentiment score.

Company Overall Sentiment
Trevena Neutral
Evelo Biosciences Neutral

13.6% of Trevena shares are owned by institutional investors. Comparatively, 0.3% of Evelo Biosciences shares are owned by institutional investors. 2.7% of Trevena shares are owned by insiders. Comparatively, 1.0% of Evelo Biosciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Trevena has higher revenue and earnings than Evelo Biosciences. Trevena is trading at a lower price-to-earnings ratio than Evelo Biosciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Trevena$443K0.14-$40.29M-$47.04N/A
Evelo BiosciencesN/AN/A-$114.53M-$0.66N/A

Company Net Margins Return on Equity Return on Assets
TrevenaN/A N/A -119.55%
Evelo Biosciences N/A N/A N/A

Trevena has a beta of -1.99, meaning that its share price is 299% less volatile than the broader market. Comparatively, Evelo Biosciences has a beta of 1.34, meaning that its share price is 34% more volatile than the broader market.

Summary

Trevena and Evelo Biosciences tied by winning 4 of the 8 factors compared between the two stocks.

How does Evelo Biosciences compare to Bio-Path?

Evelo Biosciences (NASDAQ:EVLO) and Bio-Path (NASDAQ:BPTH) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their valuation, institutional ownership, profitability, earnings, media sentiment, dividends, risk and analyst recommendations.

Evelo Biosciences' return on equity of 0.00% beat Bio-Path's return on equity.

Company Net Margins Return on Equity Return on Assets
Evelo BiosciencesN/A N/A N/A
Bio-Path N/A -2,842.40%-337.48%

Bio-Path is trading at a lower price-to-earnings ratio than Evelo Biosciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Evelo BiosciencesN/AN/A-$114.53M-$0.66N/A
Bio-PathN/AN/A-$16.08M-$1.09N/A

In the previous week, Evelo Biosciences' average media sentiment score of 0.00 equaled Bio-Path'saverage media sentiment score.

Company Overall Sentiment
Evelo Biosciences Neutral
Bio-Path Neutral

0.3% of Evelo Biosciences shares are owned by institutional investors. Comparatively, 5.7% of Bio-Path shares are owned by institutional investors. 1.0% of Evelo Biosciences shares are owned by insiders. Comparatively, 0.7% of Bio-Path shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Evelo Biosciences has a beta of 1.34, meaning that its share price is 34% more volatile than the broader market. Comparatively, Bio-Path has a beta of -0.44, meaning that its share price is 144% less volatile than the broader market.

Summary

Evelo Biosciences beats Bio-Path on 6 of the 8 factors compared between the two stocks.

How does Evelo Biosciences compare to Navidea Biopharmaceuticals?

Evelo Biosciences (NASDAQ:EVLO) and Navidea Biopharmaceuticals (NYSE:NAVB) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, earnings, media sentiment, valuation, dividends, profitability, risk and analyst recommendations.

0.3% of Evelo Biosciences shares are held by institutional investors. Comparatively, 0.0% of Navidea Biopharmaceuticals shares are held by institutional investors. 1.0% of Evelo Biosciences shares are held by company insiders. Comparatively, 43.7% of Navidea Biopharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Company Net Margins Return on Equity Return on Assets
Evelo BiosciencesN/A N/A N/A
Navidea Biopharmaceuticals N/A N/A N/A

Navidea Biopharmaceuticals has higher revenue and earnings than Evelo Biosciences. Evelo Biosciences is trading at a lower price-to-earnings ratio than Navidea Biopharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Evelo BiosciencesN/AN/A-$114.53M-$0.66N/A
Navidea Biopharmaceuticals$8.13K0.00-$15.18M-$0.21N/A

In the previous week, Evelo Biosciences' average media sentiment score of 0.00 equaled Navidea Biopharmaceuticals'average media sentiment score.

Company Overall Sentiment
Evelo Biosciences Neutral
Navidea Biopharmaceuticals Neutral

Evelo Biosciences has a beta of 1.34, suggesting that its stock price is 34% more volatile than the broader market. Comparatively, Navidea Biopharmaceuticals has a beta of 1.76, suggesting that its stock price is 76% more volatile than the broader market.

Summary

Navidea Biopharmaceuticals beats Evelo Biosciences on 5 of the 7 factors compared between the two stocks.

How does Evelo Biosciences compare to PaxMedica?

PaxMedica (NASDAQ:PXMD) and Evelo Biosciences (NASDAQ:EVLO) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, risk, dividends, valuation, media sentiment, earnings, analyst recommendations and profitability.

4.9% of PaxMedica shares are owned by institutional investors. Comparatively, 0.3% of Evelo Biosciences shares are owned by institutional investors. 1.0% of PaxMedica shares are owned by insiders. Comparatively, 1.0% of Evelo Biosciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

PaxMedica has a beta of -0.99, indicating that its stock price is 199% less volatile than the broader market. Comparatively, Evelo Biosciences has a beta of 1.34, indicating that its stock price is 34% more volatile than the broader market.

Evelo Biosciences is trading at a lower price-to-earnings ratio than PaxMedica, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
PaxMedicaN/AN/A-$18.29M-$6.09N/A
Evelo BiosciencesN/AN/A-$114.53M-$0.66N/A

Evelo Biosciences' return on equity of 0.00% beat PaxMedica's return on equity.

Company Net Margins Return on Equity Return on Assets
PaxMedicaN/A -3,167.89% -560.35%
Evelo Biosciences N/A N/A N/A

In the previous week, PaxMedica's average media sentiment score of 0.00 equaled Evelo Biosciences'average media sentiment score.

Company Overall Sentiment
PaxMedica Neutral
Evelo Biosciences Neutral

Summary

Evelo Biosciences beats PaxMedica on 5 of the 8 factors compared between the two stocks.

How does Evelo Biosciences compare to Scopus BioPharma?

Scopus BioPharma (NASDAQ:SCPS) and Evelo Biosciences (NASDAQ:EVLO) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, earnings, dividends, risk, media sentiment, profitability, analyst recommendations and institutional ownership.

In the previous week, Scopus BioPharma's average media sentiment score of 0.00 equaled Evelo Biosciences'average media sentiment score.

Company Overall Sentiment
Scopus BioPharma Neutral
Evelo Biosciences Neutral

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Scopus BioPharmaN/AN/A-$11.61MN/AN/A
Evelo BiosciencesN/AN/A-$114.53M-$0.66N/A

0.3% of Evelo Biosciences shares are owned by institutional investors. 5.1% of Scopus BioPharma shares are owned by company insiders. Comparatively, 1.0% of Evelo Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Scopus BioPharma has a beta of -0.32, meaning that its stock price is 132% less volatile than the broader market. Comparatively, Evelo Biosciences has a beta of 1.34, meaning that its stock price is 34% more volatile than the broader market.

Company Net Margins Return on Equity Return on Assets
Scopus BioPharmaN/A N/A N/A
Evelo Biosciences N/A N/A N/A

Summary

Scopus BioPharma and Evelo Biosciences tied by winning 2 of the 4 factors compared between the two stocks.

Get Evelo Biosciences News Delivered to You Automatically

Sign up to receive the latest news and ratings for EVLO and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding EVLO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

EVLO vs. The Competition

Export
MetricEvelo BiosciencesPharmaceuticals IndustryHealthcare SectorNASDAQ Exchange
Market Cap$4K$12.13B$7.18B$13.18B
Dividend YieldN/A2.63%2.52%19.60%
P/E Ratio0.00641.56203.7919.22
Price / SalesN/A749.43557.6574.70
Price / CashN/A84.0876.6852.75
Price / BookN/A9.1510.515.92
Net Income-$114.53M$2.82B$3.50B$380.90M
7 Day PerformanceN/A-3.80%-3.51%-3.85%
1 Month PerformanceN/A-7.64%-7.77%-6.37%
1 Year PerformanceN/A-6.14%0.80%-6.01%

Evelo Biosciences Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
EVLO
Evelo Biosciences
N/A$0.00
flat		N/AN/A$4KN/AN/A66
TRVN
Trevena
N/A$0.01
flat		N/A+450.0%$12K$443KN/A23
BPTH
Bio-Path
N/A$0.00
-60.0%		N/A-99.1%$11KN/AN/A10
NAVB
Navidea Biopharmaceuticals
N/AN/AN/AN/A$10K$8.13KN/A10
PXMD
PaxMedica
N/A$0.00
+40.0%		N/A+400.0%$8KN/AN/A6

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:EVLO) was last updated on 10/15/2026 by MarketBeat.com Staff.
From Our Partners
ALERT: Drop these 5 stocks before the market opens tomorrow!
The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...
Weiss Ratings | Sponsoredtc pixel
Trump's New Dollar
Porter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. doll...
Porter & Company | Sponsoredtc pixel
Small Colorado Company (Backed by Sam Altman) Could Save U.S. Power Grid
A small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...
Altimetry | Sponsoredtc pixel
Ready to give options a try? Your first trade (Ticker included) -INSIDE
Tired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...
Base Camp Trading | Sponsoredtc pixel
The end may be near for these iconic stocks
Marc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are ...
Chaikin Analytics | Sponsoredtc pixel
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
Here’s the stock symbol I’ve promised
Whitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...
Stansberry Research | Sponsoredtc pixel
Bank of America: 'Digital Dollar Inevitable'
Bank of America just revealed your expiration date. In their Bloomberg interview, they didn't just predict the...
Decentralized Masters | Sponsoredtc pixel